Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549	
------------------------	--

STATEMENT OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APF	PROVAL								
OMB Number:	3235-0287								
Estimated average burden									
hours per response:									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*				2. Issuer Name <b>and</b> Ticker or Trading Symbol  Dyne Therapeutics, Inc. [DYN]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Brumm Joshua T					-/-									X	Direc	tor		10% O	wner
(Last)	(Fir	rst) (N	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 12/11/2023									X	Office below	er (give title		Other (sbelow)	specify
C/O DYNE THERAPEUTICS, INC.					12/1	12/11/2023						See Remarks							
1560 TRAPELO ROAD					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)				-										X	Form	filed by One	e Rep	orting Pers	on
WALTH	AM MA	<b>A</b> 0	2451											Form filed by More than One Reporting Person				orting	
(City)	(Sta	ate) (Z	Zip)		Rule 10b5-1(c) Transaction Indication														
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								nded to										
		Table	I - No	on-Deriva	tive S	Secui	rities	Acc	quirec	l, Dis	posed of	, or B	enefici	ally (	Own	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/			(Year) Executi		ution Date,		Transaction Dispo		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			d 5)   S	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reported Transaction( (Instr. 3 and		ction(s)			(Instr. 4)
Common Stock 12/11/			12/11/20	2023			S		7,585(1)	D	\$10.7	72 <sup>(2)</sup> 584,		584,971(3)		D			
		Tal	ole II								osed of, convertib				wne	d			
1. Title of Derivative Security (Instr. 3)	itle of 2. 3. Transaction 3A. Deemed 4. Execution Date Execution Date, urity or Exercise (Month/Day/Year) if any Co		Transa Code (	5. Number of Derivative		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		8. Pri Deriv Secui (Instr	ative rity	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y Director Inc. (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares						

## **Explanation of Responses:**

- 1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of \$10.72 to \$10.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- 3. Includes 552,729 unvested RSUs.

## Remarks:

Chief Executive Officer and President

/s/ Richard Scalzo, Attorneyin-Fact

12/12/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.